State Medicaid agencies can improve D-SNP financial transparency and reward those D-SNPs that provide the best value to ...

We recently published a list of 10 Tech Stocks with High Upside Potential. In this article, we are going to take a look at ...

Synopsys SNPS shares plunged 20.8% over the past year, underperforming the Zacks Computer - Software industry, Zacks Computer ...

Dual eligibles — that is, people eligible for both Medicare and Medicaid — have a wealth of Medicare options. These ...

This post was written by Luke Carberry Mogan. SNPS' first-quarter performance is likely to have benefited from the rising adoption of EDA, IP solutions and Synopsys.ai platform. Get a deeper ...

Synopsys (NASDAQ:SNPS – Free Report) had its price target decreased by Piper Sandler from $655.00 to $653.00 in a report released on Thursday,Benzinga reports. Piper Sandler currently has an ...

Synopsys Inc (NASDAQ:SNPS) shares are trading higher premarket reported first-quarter financial results after the market ...

In a report released today, Blair Abernethy from Rosenblatt Securities maintained a Buy rating on Synopsys (SNPS – Research Report), with a ...

For the quarter ended January 2025, Synopsys (SNPS) reported revenue of $1.46 billion, down 11.8% over the same period last year. EPS came in at $3.03, compared to $3.56 in the year-ago quarter.

Loop Capital Markets analyst Gary Mobley reiterated a Buy rating on Synopsys (SNPS – Research Report) today and set a price target of $650.00.

A comprehensive national study examining dementia patient outcomes for Medicare Advantage beneficiaries with Alzheimer's disease and related dementias (ADRD) uncovered key insights into healthcare ...